Increased lower limb @entity508 but not strength or function following a single-dose XXXX reuptake inhibitor in @entity64 .

@entity1 @entity64 @entity18060 @entity508 @entity177 @entity837 @entity750 @entity2055
OBJECTIVE: To investigate the effects of single doses of a @entity18060 ( @entity18060 ) on lower limb @entity177 in individuals with @entity64 . DESIGN: Double-blind, randomized, placebo-controlled crossover trial. SETTING: Outpatient research setting. @entity1 : Ten individuals with post- @entity64 hemiplegia > 1 year duration (mean    standard deviation: 57  10 years; 7 males) completed all assessments. INTERVENTIONS: @entity1 were assessed prior to and 5 hours following single-dose, over-encapsulated 10 mg doses of @entity837 ( @entity18060 ) or placebo, with 1 week between conditions. MAIN OUTCOME MEASURES: Primary assessments included maximal ankle and knee isometric strength, and velocity-dependent (30-120  /s) plantarflexor stretch reflexes under passive conditions, and separately during and following superimposed maximal volitional drive to simulate conditions of increased @entity750 release. Secondary measures included clinical measures of lower limb @entity2055 and locomotion. RESULTS: @entity18060 administration significantly increased stretch reflex torques at higher stretch velocities (e.g., 90  /s; p=0.03), reflexes at lower velocities enhanced by superimposed voluntary drive (p=0.02). No significant improvements were seen in volitional peak torques or in clinical measures of lower limb function (lowest p=0.10) CONCLUSION: Increases in @entity508 but not strength or lower limb function were observed with single dose @entity18060 administration in individuals with @entity64 . Further studies should evaluate whether repeated dosing of SSRIs, or as combined with specific interventions, are required to elicit significant benefit of these agents on lower limb function post- @entity64 .
